Contract work will begin this year and calls for Emergent to deliver a total of 44.75 million doses of BioThrax. In the first contract year, 8.5 million doses are scheduled to be delivered. The vaccine will be delivered through September 2016.
The U.S. Food and Drug Administration has licensed BioThrax to protect against anthrax infection.
“This five-year award provides for uninterrupted supply of this critical biodefense countermeasure while addressing the government’s mandate to reduce spending across all programs, ” said Emergent CEO Fuad El-Hibri.